Table 1.
Demographics of Patients Included in the Study
| Variable | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
| Age, y | 40 | 33 | 47 |
| Sex | F | M | M |
| BMI (at time of transplant), kg/m2 | 28.8 | 23 | 22.3 |
| Comorbidities | Obesity, type 2 diabetes mellitus, hypertension, hyperlipidemia, hypothyroidism | None | None |
| Presenting symptoms related to COVID-19 infection | Shortness of breath, cough | Fevers, shortness of breath, cough | Fevers, shortness of breath, cough |
| Type of ventilatory/oxygenation support at time of transplant | High-flow nasal cannula | Venovenous ECMO | High-flow nasal cannula |
| Time spent on above support prior to transplant, mo | 8 | 9 | 5 |
| Complications of COVID-19 (prior to transplant) | Pneumothoraces | Pneumothoraces | Pneumothoraces with persistent bronchopleural fistulas, hydropneumothoraces, and hemothorax |
| Presumed bacterial pneumonias (culture negative) | Acute limb ischemia due to spontaneous hematoma | ||
| Nosocomial infections (Serratia marcescens, Klebsiella pneumoniae, and Pseudomonas aeruginosa bacteremia) | |||
| Nosocomial infections (P aeruginosa and K pneumoniae bacteremia; Chryseobacterium indologenes VAP; Candida krusei/glabrata candidemia) | |||
| Time between diagnosis and first negative SARS-CoV-2 PCR test, d | 38 | Unknown | 71 |
| Time between onset of COVID-19 symptoms and transplant, mo | 8 | 9 | 11 |
| ICU stay posttransplant, d | 11 | 37 | 4 |
| Posttransplant venovenous ECMO, h | 0 | 81 | 4 |
| Posttransplant ventilator, d | 2 | 25 | 1.7 (41 hours) |
| Pleural drainage, d | 10 | 8 | 7 |
BMI, body mass index; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VAP, ventilator-associated pneumonia.